158478-81-0

Basic information

• Product Name: Fmoc-HomoArg(Boc)2-OH
• Synonyms: Fmoc-HomoArg(Boc)2-OH;Fmoc-L-HomoArg- (Boc)2-OH;N6-(N,N'-Bis{[(2-methyl-2-propanyl)oxy]carbonyl}carbamimidoyl)-N2-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-lysine
• CAS NO: 158478-81-0
• Molecular Formula: C₃₂H₄₂N₄O₈
• Molecular Weight: 610.69788
• Product Categories: Amino Acids;amino acid;Fmoc Amino Acids - Arg
• Mol File: 158478-81-0.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Density: 1.24±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 3.87±0.21(Predicted)
• CAS DataBase Reference: Fmoc-HomoArg(Boc)2-OH(CAS DataBase Reference)
• NIST Chemistry Reference: Fmoc-HomoArg(Boc)2-OH(158478-81-0)
• EPA Substance Registry System: Fmoc-HomoArg(Boc)2-OH(158478-81-0)

Safety Data

• Hazardous Substances Data: 158478-81-0(Hazardous Substances Data)

Usage

General Description

Fmoc-HomoArg(Boc)2-OH is a chemical compound that often serves as a significant element in the biochemistry and molecular biology fields. Most commonly, it is used as a protective group in peptide synthesis. The 'Fmoc' in the chemical name stands for Fluorenylmethyloxycarbonyl, a base-labile protecting group, while 'Boc' refers to tert-butyloxycarbonyl, an acid-labile type of protecting group. These protective groups assist in the synthesis process by temporarily safeguarding reactive sites on the molecule until they are no longer required. As a result, the compound plays a key role in the process of creating precise, complex peptide chains, which are crucial for exploring biological phenomena such as protein behaviors.

Upstream product

• 207857-15-6 1,3-di(tert-butyloxycarbonyl)-2-(trifluoromethylsulfonyl)guanidine 
• 139262-23-0 9-fluorenylmethoxycarbonyl-L-alanine hydrochloride 
• 71989-26-9 Fmoc-Lys(tert-butoxycarbonyl) 
• 152120-54-2 N,N'-bis( tert-butoxycarbonyl)-1H-pyrazole-1-carboxamidine 
• 105047-45-8 Fmoc-Lys-OH 
• 24424-99-5 di-tert-butyl dicarbonate 
• 332882-82-3 1,3-bis(t-butoxycarbonyl)guanidine 

Relevant articles and documents

Preparation method of eptifibatide key raw material L-higher arginine

The invention discloses a preparation method of an eptifibatide key raw material L-higher arginine, and belongs to the field of synthesis of medical intermediates. The preparation method comprises thefollowing steps: reacting 1,3-bis(tert-butyloxycarbonyl)guanidine with p-toluenesulfonyl chloride to obtain 1,3-bis-Boc-2-(p-toluenesulfonyl)guanidine, then reacting the 1,3-bis-Boc-2-(p-toluenesulfonyl)guanidine with N-fluorenylmethoxycarbonyl-N'-tert-butyloxycarbonyl-L-lysine Fmoc-hArg(Boc2)-OH, removing Boc protection, and feeding Pbf-Cl to obtain N-(9-fluorenylmethoxycarbonyl)-2,2,4,6,7-pentamethyl-2H-benzofuran-5-sulfonyl-L-arginine. According to the invention, a p-toluenesulfonyl polypeptide guanidinylating agent is adopted in the route, so that ultralow-temperature reaction and the useof trifluoromethanesulfonyl chloride or trifluoromethanesulfonic anhydride with high corrosivity are avoided, and a simple and efficient way is provided for the synthesis of the intermediate.

RNA virus-derived peptides with modified side chains

The present invention provides a RNA virus-derived peptides with modified side chains, wherein the side chains of the RNA virus-derived peptide are modified by altering the side-chain length or charges thereof such that the RNA virus-derived peptide has a high binding affinity for viral RNA and an high cellular uptake capability. The present invention also provides a composition for inhibiting RNA virus wherein the RNA virus-derived peptide can effectively inhibit viral self-replication and treat related diseases by its high affinity for viral RNA. A drug delivery carrier is also provided, wherein the RNA virus-derived peptides can carry desired drugs to the intracellular target due to its cellular uptake capability and thereby enhances the drug-delivery and treating efficiency.

Assessment of structurally diverse philanthotoxin analogues for inhibitory activity on ionotropic glutamate receptor subtypes: Discovery of nanomolar, nonselective, and use-dependent antagonists

An array of analogues of the wasp toxin philanthotoxin-433, in which the asymmetric polyamine moiety was exchanged for spermine and the headgroup replaced with a variety of structurally diverse moieties, was prepared using parallel solid-phase synthesis a